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Differentiation syndrome in acute promyelocytic leukemia: pathogenesis and
risk factors
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Differentiation syndrome is a treatment complication which can occur in acute
promyelocytic leukemia (APL) patients treated with all-trans retinoic acid (ATRA) or
arsenic trioxide (ATO), which is characterized by enhanced leukocyte transmigration.
Several cellular and molecular mechanisms participate in differentiation syndrome
development. This review discusses the changes in expression of adhesion molecules
induced during ATRA and ATO treatments and their possible implications in the
pathogenesis of this potentially fatal complication. Rev. bras. hematol. hemoter.
2008;30(Supl. 2):33-36.
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The reciprocal translocation involving chromosomes
15 and 17 [t(15;17) (q22;q21)] is associated with acute
promyelocytic leukemia (APL) and leads to the fusion of the
retinoic acid receptor α (RARα ) and promyelocytic leukemia
(PML) genes thus generating the PML/RARα  hybrid gene.1
The use of all-trans retinoic acid (ATRA) and anthracycline-
based chemotherapy represents the mainstay in treatment of
APL, inducing complete hematological and molecular
remission in a high proportion of patients.2-4 ATRA induces
the malignant cells to differentiate into phenotypically mature
myeloid cells, and prompt resolution of the characteristic
coagulopathy of APL. In vitro, the differentiation process
induced by ATRA has been associated with increased
expression of integrins, cytokine release, and changes in
cellular rheology.5-8 More recently, arsenic trioxide (ATO) has
been included in the armamentarium of active drugs in APL,
being perhaps the most active single agent.9 ATO at lower
doses induces myeloid differentiation, whereas in higher
doses it induces apoptosis.
Although ATRA and ATO are well tolerated,
approximately one fourth of the patients develop the
differentiation syndrome (DS), formerly known as Retinoid
Acid Syndrome. DS was first described by Frankel et al
(1992),10 who detected this syndrome in nine of 35 (25%)
newly diagnosed APL patients. Symptoms occurred after 2
to 21 days of treatment and were generally associated with
increasing white blood cell (WBC) count and combined
fever, weight gain, dyspnea, pleural effusion, and pulmonary
infiltrates on chest radiograph and, in some patients, renal
failure, hypotension, and pericardial effusion. Six percent
to 27% of APL patients develop DS, and mortality rates
range from 1% to 7%.11-13  Our group analyzed 71 APL
patients treated with ATRA + anthracycline and observed a
DS incidence of 11.26%, with an average time for syndrome
development of 11.5 days after starting ATRA treatment
and a mortality rate of 12.5%.14 Taken together, the data in
literature reinforce the importance of early diagnosis, since
DS responds well to dexamethasone treatment (10 mg twice
daily for at least 3 days). Interestingly, the results from the
European APL Group trials suggested that, besides
corticosteroids, chemotherapy concomitant to ATRA
reduced the incidence of the syndrome, although there was
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no clear reduction in the related mortality rate.15 As mentioned
above, DS is also seen with ATO treatment. Twenty-three
percent of the APL patients in the US multicenter trial16
developed DS. All of these patients also had leukocytosis
and were treated with dexamethasone without any deaths
and without interruptions in the administration of arsenic
trioxide.
Several cellular and molecular mechanisms participate
in DS development (Figure 1). ATRA induces a variety of
effects in APL cells in vitro, including increased production
of interleukin-1 beta (IL-1β),6,17 IL-8,6 receptors for
granulocyte colony-stimulating factor (G-CSF)18 and
granulocyte-macrophage colony-stimulating factor (GM-
CSF).19 Changes in the expression of cell-surface integrins,
such as LFA-1 (CD11a/CD18) and Mac-1(CD11b/CD18), also
were demonstrated by different authors.5,20-22 Several clinical
features of DS seem to be related to these observations, in
particular, fever, fluid retention, and the migration of
differentiating myeloid cells into extravascular tissues.10
Extravascular migration of myeloid cells may be partly related
to upregulated integrin expression, which could increase
adhesion of these cells to vascular endothelium, thereby
facilitating their extravasation.20,23-24 Nevertheless, Brown
et al. (1999)25 have demonstrated that ATRA induced rolling
of NB4 cells (an APL cell line) on endothelium through the
modulation of E-selectin, without the participation of α4
integrin and P-selectin. In addition to these molecules,
intercellular adhesion molecule-1 (ICAM-1, CD54) may
further contribute to DS development since adhesion of
leukocytes to endothelial cells is an essential prerequisite
for stable arrest and transmigration of neutrophils. In fact,
levels of soluble CD54 increase in the plasma of APL patients
and decrease after the APL is cured.5
Recently, our group demonstrated a significant
increase in the expression of CD11b and ICAM-1 in ATRA-
treated NB4 cells, while in APL primary cells, in addition to
these two markers, CD18 was also up-regulated by ATRA.8
In the same study, ATO up-regulated ICAM-1 in NB4 cells
both at 0.1 and 1 µM concentration. G-CSF treatment up-
regulated CD11b expression and potentiated ATRA-induced
CD18 and CD11b expression on APL primary cells.
Importantly, we did not detect synergism between ATRA
and ATO in the upregulation of these molecules. This
observation is relevant in face of the recent results of clinical
trials using the combination of ATO and ATRA as front line
therapy for APL.26
The increase in CD11b, CD18 and CD54 expression was
accompanied by a higher adhesion to Matrigel and to
pulmonary endothelium, and was blocked by pre-incubation
with dexamethasone, anti-CD54 or anti-CD18. To test the role
of these adhesion molecules in vivo, CD54 or CD18 knock
out mice and their wild-type controls were injected with NB4
cells and treated IP with ATRA. After sacrifice, MPO activity
in the lungs was determined by colorimetric assay. These
results suggest that both leukocyte and endothelial adhesion
molecules are essential for DS development.
Gao et al (2007)27 demonstrated that in addition to IL-
1β  and IL-8, ATRA treatment could induce the expressions
of IFN-γ  in APL patient blast cells. By using human umbi-
lical cord endothelial cells (HUVECs), and human lung
microvascular endothelial cells (HLMVECs), they observed
that low doses of IFN-γ and IL-1β could synergistically
Figure 1. Cellular and molecular mechanisms participate in DS development.
ATRA treatment induces increase in the expression of adhesion molecules such as CD11b, CD18 and ICAM-1, which increase the adhesion
of myeloid to endothelial cells, thus facilitating the stable arrest and transmigration.
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iinduce apoptosis in endothelial cells with upregulated
expression of CD38 antigen. Using leukemia cells NB4 and
HL60 as a model, they presented evidence that CD38
expression promotes the binding interactions between
leukemia cells and endothelial cells.
Several features have been investigated as prognostic
for DS development. Fenaux et al. (1992)28 described that
the number of leukocytes at diagnosis correlated with DS
development. However, De Botton et al. (1998)15 analyzing
a larger cohort of patients did not detect significative
differences on leukocyte counts at diagnosis between
patients that developed or not DS. It is interesting to note
that Vahdat et al. (1999)11 also did not find correlation
between the number of leukocytes and DS development
but, on the contrary, the maximum value of this number
after the introduction of ATRA presented important
association. In addition, Tallman et al. (2000)3 had affirmed
that patients with microgranular variant M3v of APL appear
to be protected from the syndrome, but these findings had
not been confirmed in posterior studies.14
Considering the relevance of ICAM1 in leukocyte
infiltration and the effect of ATRA and ATO on its expression,
we decided to analyze the role of ICAM1 polymorphisms in
DS development. We included PECAM-1 (platelet-endothelial
cell adhesion molecule-1) polymorphisms since it is
constitutively expressed by most circulating leukocytes,
platelets and endothelial cells, and both adhesion molecules
are involved in endothelium integrity and extravasation of
cells from the blood compartment into the vessel and
underlying tissue.29 We analyzed 127 APL patients of whom
23 developed DS. Only patients with respiratory distress
accompanied by pulmonary infiltrates were analyzed.
Regarding age, gender, WBC counts, hemoglobin and
platelets values, no predictive factor of DS development in
APL patients could be found. Considering genetic
variations in adhesion molecules ICAM-1 and PECAM-1
we detected no significant association between ICAM-1
G241R or PECAM-1 L125V polymorphisms and DS. On the
other hand, the AA genotype at codon 469 of ICAM-1 was
significantly associated to DS in APL patients.30 The 469 E/
K polymorphism in exon 6 results in a change from glutamic
acid to lysine in Ig-like domain 5 of ICAM-1, which is thought
to affect interactions with LFA-1 and adhesion of B-cells.
The functional effect of this polymorphism is still unclear,
but it may influence disease susceptibility.
In conclusion, DS is a multifactorial process and the
activation of adhesion molecules by ATRA and ATO are
triggering events. Genetic determinants, such as ICAM-1
polymorphisms, may play a role in its pathogenesis and larger
multicentric studies are necessary to establish the value these
markers as risk factors in DS development.
Resumo
A síndrome da diferenciação (DS) é um efeito colateral que pode
ocorrer em pacientes com leucemia promielocítica aguda (APL)
tratados com ácido all-trans-retinóico (ATRA) ou trióxido de arsênico
(ATO), sendo caracterizada pelo aumento da transmigração de
leucócitos. Vários mecanismos celulares e moleculares participam
no desenvolvimento da DS. Esta revisão discute as mudanças na
expressão de moléculas de adesão induzidas durante o tratamento
com ATRA e ATO e possíveis implicações na patogênese desta
complicação potencialmente fatal. Rev. bras. hematol. hemoter.
2008;30(Supl. 2):33-36.
Palavras-chave: Leucemia promielocítica aguda; moléculas de ade-
são; retinóides; trióxido de arsênico.
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